endometrial cancer

News

Keytruda shadows GSK's Jemperli in endometrial cancer

GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck &

News

GSK cancer division delivers good news after string of R&D s...

GSK has reported much-needed progress with two of its cancer therapies, with a phase 3 trial win for immunotherapy Jemperli in endometrial cancer and the start of a review in the EU for mye

News

Scotland backs three new uses for MSD's Keytruda

Scotland has become the first country in the UK to back NHS funding for the use of Merck & Co/MSD's Keytruda in combination with Eisai's Lenvima as a treatment for advanced or recurrent

News

Keytruda encroaches on Jemperli's endometrial cancer territo...

Merck & Co's KEYNOTE-158 trial of Keytruda has underpinned another FDA approval, this time for the PD-1 inhibitor as a single-agent therapy as a therapy for endometrial cancer with cert

News

NICE clears use of GSK's Jemperli in endometrial cancer

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli vi

News

FDA approves under-pressure GSK's Jemperli for endometrial c...

The FDA has approved GlaxoSmithKline’s Jemperli (dostarlimab) immunotherapy, a drug acquired through its $5.1 billion acquisition of Tesaro, for certain patients with endometrial cancer.

Keytruda shadows GSK's Jemperli in endometrial cancer

GSK cancer division delivers good news after string of R&D s...

Scotland backs three new uses for MSD's Keytruda

Keytruda encroaches on Jemperli's endometrial cancer territo...

NICE clears use of GSK's Jemperli in endometrial cancer

FDA approves under-pressure GSK's Jemperli for endometrial c...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

endometrial cancer

Editor's Picks